^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TNFRSF14 expression

    i
    Other names: TNFRSF14, TNF Receptor Superfamily Member 14, HVEA, HVEM, TR2, Tumor Necrosis Factor Receptor Superfamily, Member 14 (Herpesvirus Entry Mediator), Tumor Necrosis Factor Receptor Superfamily Member 14, Herpes Virus Entry Mediator A, LIGHTR, CD270, ATAR, Tumor Necrosis Factor Receptor Superfamily, Member 14, Tumor Necrosis Factor Receptor-Like Gene2, Tumor Necrosis Factor Receptor-Like 2, Herpesvirus Entry Mediator A, Herpesvirus Entry Mediator, CD40-Like Protein, CD270 Antigen, HveA
    Entrez ID:
    8764
    Related biomarkers:
    Expression
    Mutation
    over1year
    Exploration of tertiary lymphatic structure in soft tissue sarcoma for the prognostic and immunotherapy response (ESMO 2023)
    Conclusions The TLS-Total gene set, TLS-related prognostic signature, TNFRSF14, and DUSP9 selected in this study can predict the prognosis of patients with soft tissue sarcoma. TNFRSF14 and DUSP9 are associated with immune cell infiltration, which can indicate the efficacy of immunotherapy and may become new predictive markers of immunotherapy efficacy.
    IO biomarker
    |
    TNFRSF14 (TNF Receptor Superfamily Member 14)
    |
    TNFRSF14 expression
    2years
    The Pyroptosis-Related Risk Genes APOBEC3D, TNFRSF14, and RAC2 Were Used to Evaluate Prognosis and as Tumor Suppressor Genes in Breast Cancer. (PubMed, J Oncol)
    Based on pyroptosis-related genes (APOBEC3D, TNFRSF14, and RAC2), we built a novel prognostic molecular model for BC that might be used to assess prognostic risk and immune infiltration in BC patients. These signature genes are also tumor suppressor genes and may serve as potential targets for BC.
    Journal
    |
    TNFRSF14 (TNF Receptor Superfamily Member 14) • TNFRSF18 (TNF Receptor Superfamily Member 18) • RAC2 (Rac Family Small GTPase 2)
    |
    TNFRSF14 expression